文献速递肾小球疾病

口服脾酪氨酸激酶抑制剂治疗IgA肾病的随机试验

Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2023-09-30

这项双盲随机安慰剂对照2期试验纳入76例IgA肾病患者,在最大耐受剂量RAS抑制剂基础上加用fostamatinib(口服SYK抑制剂)100mg或150mg每日两次治疗24周。总体未显著降低蛋白尿,但在基线UPCR>1000mg/g的预定亚组中呈剂量依赖性下降趋势(14%、27%、36%)。

要点

  • fostamatinib总体未显著降低蛋白尿,但高UPCR亚组呈剂量依赖下降趋势。
  • 所有组eGFR保持稳定,药物耐受性良好,副作用包括腹泻、高血压和肝酶升高。
  • 重复活检显示低剂量组SYK染色减少(-1.5 vs 1.7 SYK+细胞/肾小球,P<0.05)。

核心结论

  • 在基线UPCR>1000mg/g的预定高危亚组分析中,fostamatinib有降低蛋白尿的趋势,尽管总体未达显著。
  • fostamatinib在IgA肾病患者中耐受性良好,肾功能保持稳定。

研究设计与样本

  • 双盲、随机、安慰剂对照2期试验,纳入76例IgA肾病患者。
  • 患者随机接受安慰剂、fostamatinib 100mg或150mg每日两次,共24周,均叠加最大耐受剂量RAS抑制剂。

主要发现

  • 总体未检测到蛋白尿显著降低。
  • 基线UPCR>1000mg/g患者中,中位蛋白尿从基线至24周下降:安慰剂14%、100mg组27%、150mg组36%(剂量依赖趋势)。
  • 所有组eGFR保持稳定,fostamatinib耐受性良好。
  • 副作用包括腹泻、高血压和肝酶升高。

关键数值与推荐

  • 主要终点为蛋白尿降低。
  • 次要终点包括eGFR和肾脏组织学从基线的变化。
  • 基线UPCR>1000mg/g为预定亚组分析条件。

临床怎么用

  • 对于基线UPCR>1000mg/g的IgA肾病患者,fostamatinib可能具有降低蛋白尿的潜力,但需进一步研究验证。
  • 使用fostamatinib时需监测腹泻、高血压和肝酶升高等副作用。

局限性

  • 总体未达到显著降低蛋白尿的主要终点。
  • 高UPCR亚组仅为趋势性结果,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We reported increased spleen tyrosine kinase (SYK) expression in kidney biopsies of patients with IgA nephropathy (IgAN) and that inhibition of SYK reduces inflammatory cytokines production from IgA stimulated mesangial cells. METHODS: This study was a double-blind, randomized, placebo-controlled phase 2 trial of fostamatinib (an oral SYK inhibitor) in 76 patients with IgAN. Patients were randomized to receive placebo, fostamatinib at 100 mg or 150 mg twice daily for 24 weeks on top of maximum tolerated dose of renin-angiotensin system inhibitors. The primary end point was reduction of proteinuria. Secondary end points included change from baseline in estimated glomerular filtration rate (eGFR) and kidney histology. RESULTS: Although we could not detect significant reduction in proteinuria with fostamatinib overall, in a predetermined subgroup analysis, there was a trend for dose-dependent reduction in median proteinuria (from baseline to 24 weeks by 14%, 27%, and 36% in the placebo, fostamatinib 100 mg, and 150 mg groups, respectively) in patients with baseline urinary protein-to-creatinine ratios (UPCR) more than 1000 mg/g. Kidney function (eGFR) remained stable in all groups. Fostamatinib was well-tolerated. Side effects included diarrhea, hypertension, and increased liver enzymes. Thirty-nine patients underwent repeat biopsy showing reductions in SYK staining associated with therapy at low dose (-1.5 vs. 1.7 SYK+ cells/glomerulus in the placebo group, P < 0.05). CONCLUSIONS: There was a trend toward reduction in proteinuria with fostamatinib in a predefined analysis of high risk patients with IgAN despite maximal care, as defined by baseline UPCR greater than 1000 mg/g. Further study may be warranted.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tam FWK, Tumlin J, Barratt J, et al. Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy. Kidney Int Rep. 2023. PMID: 38106605. doi:10.1016/j.ekir.2023.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。